Business
Co-Diagnostics Receives Japanese Patent Covering Co-Dx PCR Platform Technologies
SALT LAKE CITY, March 12, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique,
About this update from Co-diagnostics, Inc.
[{"type":"text","content":"SALT LAKE CITY, March 12, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (\"Co-Dx\" or \"the Company\"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Japan Patent Office (\"JPO\") has granted Japanese Patent No. 7797537, titled \"Systems, Methods, and Apparatus for Automated Self-Contained Biological Analysis.\" The patent further strengthens Co-Dx's intellectual property portfolio and supports the innovativeness of its novel Co-Dx PCR Pro® instrument, test cups, and other aspects of the point-of-care platform*.\n \n \n \n \n \n \n \nInitially registered on December 26, 2025, the patent includes 34 claims and was filed under the Patent Cooperation Treaty (PCT) to allow the Company to pursue coordinated international protection in countries around the world with a single application.\"The Japan Patent Office is considered one of the world's most rigorous and meticulous in its review process,\" said Dwight Egan, Chief Executive Officer of Co-Diagnostics. \"We believe that receiving such a comprehensive patent by the JPO illustrates the uniqueness and innovation of the Co-Dx platform, and its potential for transforming how and where infectious diseases are diagnosed. This patent reinforces the global protection of our platform technologies and supports our strategy to expand access to affordable, high-performance point-of-care PCR testing solutions worldwide.\"The issuance follows the patent granted by the Australian Patent Office in 2025 and further expands the Company's growing patent portfolio, which is designed to protect the Co-Dx PCR platform and associated technologies in key international markets. By securing intellectual property rights in Japan, Co-Diagnostics strengthens its competitive positioning and enhances its ability to pursue commercial opportunities, partnerships, and regulatory initiatives in the region.Co-Diagnostics' Co-Dx PCR point-of-care system is designed to deliver gold-standard PCR accuracy in a compact, user-friendly device suitable for decentralized testing environments. The platform leverages the Company's patented Co-Primers® technology and aims to enable rapid, sensitive, and specific molecular diagnostics across a broad range of applications.The 34 claims in the patent cover the fundamental sys...